The Journal of Urology
Volume 183, Issue 4 , Pages 1432-1437 , April 2010

Under Treatment of Overactive Bladder Symptoms in Patients With Multiple Sclerosis: An Ancillary Analysis of the NARCOMS Patient Registry

  • S.T. Mahajan

      Affiliations

    • Department of Obstetrics and Gynecology and Urology, University Hospitals Case Medical Center, Cleveland, Ohio
    • Corresponding Author InformationCorrespondence: 11100 Euclid Ave., MAC 5034, Cleveland, Ohio 44106 (telephone: 216-844-4906; FAX: 216-844-5167)
    • Financial interest and/or other relationship with Pfizer, Inc. and Duramed.
    • ,
  • P.B. Patel

      Affiliations

    • Department of Obstetrics and Gynecology and Urology, University Hospitals Case Medical Center, Cleveland, Ohio
    • ,
  • R.A. Marrie

      Affiliations

    • Internal Medicine and Community Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada

Received 13 August 2009

References 

  1. Noseworthy JH, Lucchinetti C, Rodriguez M, et al. Multiple sclerosis. N Engl J Med. 2000;343:938
  2. Nortvedt M, Riise T, Myhr KM, et al. Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler. 2001;7:231
  3. Wiesel PH, Norton C, Glickman S, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001;13:441
  4. Borello-France D, Leng W, O'Leary M, et al. Bladder and sexual function among women with multiple sclerosis. Mult Scler. 2004;10:455
  5. Andrews KL, Husmann DA. Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc. 1997;72:1176
  6. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63:153
  7. Marrie RA, Cutter G, Tyry T, et al. Disparities in the management of multiple sclerosis-related bladder symptoms. Neurology. 2007;68:1971
  8. Schwartz CE, Vollmer T, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. North American Research Consortium on Multiple Sclerosis Outcomes Study Group. Neurology. 1999;52:63
  9. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45:251
  10. Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a longitudinal study comparing disease steps and EDSS to evaluate disease progression. Mult Scler. 1999;5:349
  11. Kurtzke J. Rating disability in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:144
  12. Gandek B, Ware JE, Aaronson NK, et al. Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project (International Quality of Life Assessment). J Clin Epidemiol. 1998;51:1171
  13. Burdine JN, Felix MR, Abel AL, et al. The SF-12 as a population health measure: an exploratory examination of potential for application. Health Serv Res. 2000;35:885
  14. Uebersax JS, Wyman JF, Shumaker SA, et al. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Neurourol Urodyn. 1995;14:131
  15. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract dysfunction: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn. 2002;21:167
  16. Hennessey A, Robertson NP, Swingler R, et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999;246:1027
  17. Stewart W, Herzog A, Wein A, et al. Prevalence and impact of overactive bladder in the US: results from the NOBLE Program. Neurourol Urodyn. 2001;20:406
  18. Chapple CR, Van Kerrebroeck PE, Junemann KP, et al. Comparison of fesoterodine and tolterodine in patients with overactive bladder. BJU Int. 2008;102:1128
  19. Chancellor M, Zinner N, Whitmore K, et al. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study. Clin Ther. 2008;30:1766
  20. Bolge SC, McDonnell DD, Chen A, et al. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin. 2007;23:1903
  21. Urinary Dysfunction and Multiple Sclerosis (Evidence-Based Strategies for Urinary Dysfunction in Multiple Sclerosis). Washington, DC: Paralyzed Veterans of America; 1999;
  22. Litwiller SE, Frohman EM, Zimmern PE. Multiple sclerosis and the urologist. J Urol. 1999;161:743
  23. Nakash RA, Hutton JL, Lamb SE, et al. Response and non-response to postal questionnaire follow-up in a clinical trial–a qualitative study of the patient's perspective. J Eval Clin Pract. 2008;14:226

 See Editorial on page 1282.

PII: S0022-5347(09)03193-0

doi: 10.1016/j.juro.2009.12.029

The Journal of Urology
Volume 183, Issue 4 , Pages 1432-1437 , April 2010

Article Tools

* Image Usage & Resolution